SCHEMBL258369

SCHEMBL258369

CCCc1ccncc1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 11/20 0.51
KDM6B O15054 7/20 0.51
KDM4E B2RXH2 3/20 0.46
KDM4D Q6B0I6 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
KDM4A O75164 2/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
THRB P10828 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.44
GABRP O00591 3/20 0.43
GABRD O14764 3/20 0.43
GABRA1 P14867 3/20 0.43
GABRB1 P18505 3/20 0.43
GABRG2 P18507 3/20 0.43
GABRB3 P28472 3/20 0.43
GABRA5 P31644 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5739434 0.98 KDM4C (0.50) KDM4CKDM6BKDM4EKDM4DTDP1
SCHEMBL4005290 0.90 GABRP (0.55) KDM4CKDM6BKDM4EKDM4DTDP1
SCHEMBL123203 0.87 KDM4C (0.51) KDM4CKDM6BKDM4EKDM4DTDP1
SCHEMBL30465694 0.87 KDM4C (0.51) KDM4CKDM6BKDM4EKDM4DTDP1
SCHEMBL5002411 0.87 KDM6B (0.51) KDM4CKDM6BPTGDR2GABRPGABRD
SCHEMBL4998341 0.87 KDM6B (0.51) KDM4CKDM6BPTGDR2GABRPGABRD
SCHEMBL4998464 0.87 KDM6B (0.51) KDM4CKDM6BPTGDR2GABRPGABRD
SCHEMBL6072747 0.87 KDM6B (0.51) KDM4CKDM6BPTGDR2GABRPGABRD
SCHEMBL5002870 0.87 KDM6B (0.51) KDM4CKDM6BPTGDR2GABRPGABRD
SCHEMBL9698166 0.86 KDM4C (0.55) KDM4CKDM6BKDM4EKDM4DTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1517880-B1 PRODUCTION OF CIS-PELLITORIN AND USE AS A FLAVOURING SYMRISE AG (DE) 2011-01-05 EP claimed
EP-1633334-B1 TOPICAL ADMINISTRATION OF VASOACTIVE VITAMIN B3 COMPOUNDS FOR PROMOTING SLEEP PROCTER & GAMBLE (US) 2006-11-15 EP claimed
EP-1335715-B1 SKIN-FRIENDLY AND DRUG-CONTAINING PATCHES FOR TRANSDERMAL ADMINISTRATION OF HYPEREMIC ACTIVE INGREDIENTS BEIERSDORF AG (DE) 2005-05-11 EP claimed
EP-1335715-A2 SKIN FRIENDLY ACTIVE INGREDIENT PLASTER FOR TRANSDERMAL ADMINISTRATION OF RUBEFACIENT ACTIVE INGREDIENTS Beiersdorf AG (DE) 2003-08-20 EP claimed
EP-0846463-B1 Active substance containing plaster BEIERSDORF AG (DE) 2003-02-26 EP claimed
WO-2002038137-A2 SKIN FRIENDLY ACTIVE INGREDIENT PLASTER FOR TRANSDERMAL ADMINISTRATION OF RUBEFACIENT ACTIVE INGREDIENTS BEIERSDORF AG (DE) 2002-05-16 WO claimed
EP-0846463-A2 Active substance containing plaster Beiersdorf Aktiengesellschaft (DE) 1998-06-10 EP claimed
WO-1992012699-A1 COSMETIC OR PHARMACEUTICAL COMPOSITIONS FOR IMPROVING HAIR QUALITY AND PROMOTING HAIR GROWTH WEUFFEN WOLFGANG (DE) 1992-08-06 WO claimed
EP-4699452-A2 OBTAINING A VOLATILE FRACTION FROM JUICES OR ALCOHOLIC BEVERAGES Symrise AG (DE) 2026-02-25 EP disclosed
US-20260041109-A1 ROBUST FLAVOR EMULSIONS INT FLAVORS & FRAGRANCES INC (US) 2026-02-12 US disclosed
EP-3836799-B1 OBTAINING A VOLATILE FRACTION FROM JUICES OR ALCOHOLIC BEVERAGES SYMRISE AG (DE) 2025-11-26 EP disclosed
US-12419815-B2 Microcapsule compositions stabilized with viscosity control agents INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 2025-09-23 US disclosed
EP-4615958-A1 CELL COMPOSITIONS Givaudan SA (CH) 2025-09-17 EP disclosed
US-12357547-B2 Compositions containing microcapsules INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 2025-07-15 US disclosed
WO-2002024857-A1 MULTI-PHASE SOAP HAARMANN & REIMER GMBH (DE) 2002-03-28 WO disclosed
EP-0846463-A2 Active substance containing plaster Beiersdorf Aktiengesellschaft (DE) 1998-06-10 EP disclosed
WO-1992012699-A1 COSMETIC OR PHARMACEUTICAL COMPOSITIONS FOR IMPROVING HAIR QUALITY AND PROMOTING HAIR GROWTH WEUFFEN WOLFGANG (DE) 1992-08-06 WO disclosed
US-4046768-A 1-Thiazolyl-5-pyridylcarbonyloxyimidazolidinones VELSICOL CHEMICAL CORPORATION (US) 1977-09-06 US disclosed
US-4045446-A 1-Benzothiazolyl-5-pyridylcarbonyloxyimidazolidinones VELSICOL CHEMICAL CORPORATION (US) 1977-08-30 US disclosed
US-4033753-A HERICIDES VELSICOL CHEMICAL CORPORATION (US) 1977-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12357547-B2 Compositions containing microcapsules COPE, SAAL1, AUP1 KDM4C 4468/4885KDM6B 4480/4885KDM4E 4001/4885
US-12419815-B2 Microcapsule compositions stabilized with viscosity control agents ACR, ALG1, MLEC KDM4C 4508/4885KDM6B 4611/4885KDM4E 4393/4885
US-20260041109-A1 ROBUST FLAVOR EMULSIONS ACACA, FABP4, CUTA KDM4C 4017/4885KDM6B 4525/4885KDM4E 4681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.